Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Taking a Break https://t.co/QgH851GMZX #Science #Business
    about 2 days ago
  • Total venture capital funding in the U.S. for first six months of 2019 reached levels not seen since the year 2000,… https://t.co/cGSC6j1Xl8
    about 2 days ago
  • New post on Science and Enterprise: Infographic – U.S. Venture Funds Near 20-Year Highs https://t.co/mIkraoGRAH #Science #Business
    about 2 days ago
  • A set of computational tools developed at Purdue University enables public safety agencies to monitor potentially c… https://t.co/NHSLm9YBBG
    about 3 days ago
  • New post on Science and Enterprise: A.I. Helps Visualize Emergency Social Media Data https://t.co/E94lXHnPsa #Science #Business
    about 3 days ago

Please share Science & Enterprise

Hearing Loss Cell Therapy Licensed in $625M Deal

Man with headphones

A biotechnology company developing regenerative treatments for various disorders is licensing its lead therapy candidate for hearing loss to Astellas Pharma. . . . → Read More: Hearing Loss Cell Therapy Licensed in $625M Deal

Genentech, Biotech Partner on Multiple Sclerosis

Neurons illustration

A company designing treatments to restore the protective coating on nerve cells damaged by multiple sclerosis is collaborating with biotechnology enterprise Genentech. . . . → Read More: Genentech, Biotech Partner on Multiple Sclerosis

Trial Shows Immunotherapies Extend Life with Melanoma

T-cell lymphocyte

First results from a clinical trial show a combination of immunotherapies extends survival among patients with melanoma, but shorter periods for other solid-tumor cancers. . . . → Read More: Trial Shows Immunotherapies Extend Life with Melanoma

Crispr Enhanced for RNA Editing

Feng Zhang

Researchers expanded the ability of the genetic editing technique known as Crispr to alter the make-up of RNA, adding more ways to treat diseases. . . . → Read More: Crispr Enhanced for RNA Editing

Voice Indicators to Monitor Dementia Progression

Brain circuits illustration

A company developing diagnostics for cognitive disorders from changes in speech patterns is partnering on vocal biomarkers to track progression of a form of dementia. . . . → Read More: Voice Indicators to Monitor Dementia Progression

Immunotherapy Biotech Gains $325M in Venture Funds

Investment graphic

A biotechnology enterprise developing personalized treatments for cancer and infectious diseases is raising $325 million in its second venture funding round. . . . → Read More: Immunotherapy Biotech Gains $325M in Venture Funds

Stem Cell Start-Up Raises $250M in Venture Funds

T-cell lymphocyte

A company begun last year to create cancer therapies from banked, off-the-shelf stem cells is raising $250 million in its first round of venture financing. . . . → Read More: Stem Cell Start-Up Raises $250M in Venture Funds

Trial Testing Paramedic-Delivered Stroke Drug

Ambulance

A clinical trial is getting underway testing a treatment for stroke delivered to patients by emergency medical technicians on the way to the hospital. . . . → Read More: Trial Testing Paramedic-Delivered Stroke Drug

Artificial DNA Designed to Control Drug Delivery

DNA nanoparticle release

Researchers in Germany are developing techniques with artificial DNA and hydrogel designed to control the sequence of drugs delivered into the body. . . . → Read More: Artificial DNA Designed to Control Drug Delivery

Two Biotechs Each Issue $300M+ IPOs

NASDAQ share price display

Two biotechnology enterprises in the U.S. issued their initial public stock offerings yesterday, with each company raising at least $300 million in their transactions. . . . → Read More: Two Biotechs Each Issue $300M+ IPOs